Trials / Terminated
TerminatedNCT01351675
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,185 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Oral, once daily |
| DRUG | Bardoxolone Methyl: 20 mg | 20 mg, oral, once daily |
Timeline
- Start date
- 2011-06-30
- Primary completion
- 2012-10-31
- Completion
- 2012-12-31
- First posted
- 2011-05-11
- Last updated
- 2025-05-29
Source: ClinicalTrials.gov record NCT01351675. Inclusion in this directory is not an endorsement.